[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100364843":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":34,"centralContacts":38,"locations":47,"responsibleParty":65,"collaborators":68,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":22,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":22,"enrollmentInfo":82,"targetDuration":22,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":95,"overallStatus":49,"whyStopped":22,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Brigham and Women's Hospital","OTHER",[8,14,18,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Inflammatory Breast Cancer Managed with Curative Intent","EXPERIMENTAL","* Patients will receive an initial screening magnetic resonance imaging (MRI) of the brain\n* If no evidence of intracranial involvement is identified, additional screening MRIs of the brain every six months for two years and at initial systemic progression.",[13],"Device: MRI",{"label":15,"type":10,"description":16,"interventionNames":17},"HR+ or HER2+ Metastatic Breast Cancer - Screening Arm","* An initial MRI screening will be conducted\n* If negative, patients will receive a second MRI of the brain at first systemic progression after study entry",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"HR+ or HER2+ Metastatic Breast Cancer - No Screening Arm","NO_INTERVENTION","No initial MRI screening will be conducted",null,{"label":24,"type":10,"description":16,"interventionNames":25},"Triple Negative Breast Cancer",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DEVICE","MRI","MRI (which stands for magnetic resonance imaging) provide imaging of the brain which help look for brain metastases (spread of the breast cancer to the brain).",[15,9,24],[33],"Magnetic Resonance Imaging",[35],{"name":36,"affiliation":5,"role":37},"Ayal Aizer, MD, MHS","PRINCIPAL_INVESTIGATOR",[39,43],{"name":36,"role":40,"phone":41,"phoneExt":22,"email":42},"CONTACT","617-732-7560","aaaizer@partners.org",{"name":44,"role":40,"phone":45,"phoneExt":22,"email":46},"Ivy Ricca, BA","6175828927","iricca@mgb.org",[48],{"facility":5,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"RECRUITING","Boston","Massachusetts","02115","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-71.05977,42.35843,{"lat":59,"lon":58},[62,64],{"name":63,"role":40,"phone":41,"phoneExt":22,"email":42},"Ayal Aizer",{"name":36,"role":37,"phone":22,"phoneExt":22,"email":22},{"type":37,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"Ayal A. Aizer, MD","Principal Investigator",[69,71],{"name":70,"class":6},"Conquer Cancer Foundation",{"name":72,"class":6},"Dana-Farber Cancer Institute","100364843","screening-magnetic-resonance-imaging-of-the-brain-in-patients-with-breast-cancer-100364843",false,"NCT04030507","Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer","Screening Magnetic Resonance Imaging of the Brain in Patients With Metastatic Breast Cancer Managed With First\u002FSecond Line Chemotherapy or Inflammatory Breast Cancer Managed With Definitive Intent: A Prospective Study","Inclusion Criteria:\n\n* Participants must have histologically or cytologically confirmed breast cancer with pathologic assessment of estrogen receptor (ER), progesterone receptor (PR), and (human epidermal growth factor receptor 2 (HER2) status. If subtype has changed over the course of a patient's disease, the treating clinician and\u002For study PI is responsible for selecting the subtype that most likely reflects the preponderance of oncologic disease at the time of enrollment.\n* Participants must have radiographic evidence of extracranial, distant metastases or unresectable, locally recurrent breast cancer and be initiating (within 8 weeks of registration) first-line or second-line chemotherapy for their metastatic\u002Frecurrent disease OR inflammatory breast cancer being managed with curative intent within six months of diagnosis.\n* Participants must be age 18 years or older.\n* Participants must have a life expectancy of greater than 12 weeks.\n* Participants must be willing to undergo study procedures.\n* The effects of gadolinium \u002F other magnetic resonance imaging (MRI)-based contrast agents on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.\n* Participants must possess the ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Participants who have a contraindication to MRI (e.g. noncompatible implanted metallic device for which MRI is absolutely contraindicated).\n* Participants who have chronic kidney disease stage IV-V or end stage renal disease.\n* Participants with a history of anaphylactic reactions to gadolinium.\n* Pregnant women are excluded from this study because gadolinium-based agents have not been proven to be safe to administer to a developing fetus. Similarly, breastfeeding women will be excluded from this study.\n* Patients with a prior diagnosis of brain metastases","ALL","18 Years",{"count":83,"type":84},214,"ESTIMATED","INTERVENTIONAL",[87],"NA","This research study is studying the usefulness of magnetic resonance imaging (MRI) to screen for brain metastases (spread of the breast cancer to the brain).",[90,91,24,92,93,94],"Breast Cancer","HER2-positive Breast Cancer","Hormone Receptor Positive Malignant Neoplasm of Breast","Inflammatory Breast Cancer","Metastatic Breast Cancer",[90,91,24,92,93,96],"Metastatic breast cancer","2026-03-17",{"date":99,"type":100},"2026-03-19","ACTUAL",{"date":102,"type":100},"2019-07-26",{"date":104,"type":84},"2028-02",{"name":5,"class":6},1]